PDS Biotechnology Corpora... (PDSB)
NASDAQ: PDSB
· Real-Time Price · USD
1.33
0.06 (4.72%)
At close: Jul 03, 2025, 3:59 PM
1.35
1.42%
After-hours: Jul 03, 2025, 04:17 PM EDT
4.72% (1D)
| Bid | 1.3 |
| Market Cap | 60.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.5M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -1.41 |
| Forward PE | -1.49 |
| Analyst | Buy |
| Ask | 1.35 |
| Volume | 141,463 |
| Avg. Volume (20D) | 511,080 |
| Open | 1.29 |
| Previous Close | 1.27 |
| Day's Range | 1.26 - 1.34 |
| 52-Week Range | 0.85 - 4.42 |
| Beta | 1.24 |
About PDSB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PDSB
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for PDSB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-0.63%
PDS Biotechnology shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago
-8.21%
PDS Biotechnology shares are trading higher after the company announced the initiation of its VERSATILE-003 Phase 3 clinical trial.
1 month ago · proactiveinvestors.co.uk
EMV Capital portfolio company PDS Biotech advances cancer trialPDS Biotechnology Corporation (NASDAQ:PDSB), a US cancer immunotherapy firm backed by EMV Capital (AIM:EMVC), has begun site activations for its phase III trial of Versamune HPV in patients with head ...
1 month ago · seekingalpha.com
PDS Biotechnology Corporation (PDSB) Q1 2025 Earnings Call TranscriptPDS Biotechnology Corporation (NASDAQ:PDSB ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Frank Bedu-Addo - CEO Lars Boesgaard - CFO Kirk Shepard - Chief Medical Offic...